Casdin Partners Confirms $28.1M Stock Sale, Reduces Stake to 9.7%
BLFS sits 34% above its 52-week low of $17.86 on elevated volume (2.0× avg).
Summary
Major institutional investor Casdin Partners confirmed the sale of $28.1 million worth of BioLife Solutions stock, reducing its stake to 9.7% after previously signaling intent to sell.
Key Events · Ownership and Investor Activity · BLFS
-
Significant Stake Reduction Confirmed
Casdin Partners, a major institutional investor, reported the sale of 1,200,000 shares of BioLife Solutions common stock.
-
$28.1 Million in Sales Executed
The shares were sold in multiple transactions between May 19-21, 2026, for a total value of approximately $28.1 million.
-
Ownership Reduced to 9.7%
Following these sales, Casdin Partners' beneficial ownership in BioLife Solutions has decreased to 9.7% of the outstanding shares.
-
Follows Prior Intent to Sell
This Schedule 13D/A confirms the execution of sales previously indicated by multiple Form 144 filings from Casdin Partners in the days leading up to this report.
Analysis · BLFS · Industrial Applications And Services
Casdin Partners, a significant institutional investor, has reported the sale of 1.2 million shares of BioLife Solutions common stock for approximately $28.1 million. This transaction, which reduces their beneficial ownership to 9.7%, confirms the execution of sales previously indicated by a series of Form 144 filings. The substantial reduction in their position, representing over 20% of their prior holdings, signals a significant change in their investment strategy.
At the time of this filing, BLFS was trading at $23.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $17.86 to $29.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.